Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Prescribe Right Pharmaceutical Pipeline Update for August 21

8/21/2018

 
Six updates we identified from over 200 Informational feeds from research presentations, study publication and news about drugs in development.
​
  • Interim data from the first 16-weeks of a 36-week, 646 patient, Phase III trial, found that patients treated with fasinumab (from Teva, Regeneron) had an improvement in WOMAC scores compared to placebo in patients with osteoarthritis of the knee or hip. Patients treated with fastinumab every 4 weeks or 8 weeks had an improvement in pain (2.78, 2. 25) compared to placebo (1.59) and physical function was improved 2.57 to 2.10 compared to 1.37 with placebo.
  • The FDA granted Motif Bio’s iclaprim a priority review on 8/14/18. Iclaprim Is given as a 2-hour infusion Q12 hr. In four Phase III skin infections trials the most common ADR for iclaprim were headache, nausea, vomiting, fatigue. It is the only DHFR- Inhibitor in our investigational knowledgebase. It’s indication is acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia.
  • ViiV announced that in the 48-week, Phase III Atlas Trial, cabotegravir and rilpivirine,injected monthly was comparable in HIV viral suppression to a three drug oral regimen of 2 NRTIs plus a third drug. In a 96-week, 243 patient, Phase IIb trial, daily oral cabotegravir plus rilpivirine was comparable to efavirenz plus dual NRTIs in HIV viral suppression. Cabotegravir/rilpivirine is the only investigational entity within the INSTI/NNRT drug class in our knowledgebase.
  • In a 431 patient, Phase III trial, patients treated with Medivation’s talazoparib had a PFS of 3 months longer than standard chemotherapy in patients with advanced breast cancer who carry the BRCA1 and BRCA2 mutations. 
  • Gemphire Therapeutics has discontinued a trial evaluating use of gemcabene in the treatment of pediatric nonalcoholic fatty liver disease due to worsening of the disease in some patients
  • In a 439-patient, Phase III trial, anlotinib (by Jiangsu Chiatai Qingjiang; Advenchen) improved OS versus placebo by 3.3 months and PFS by 4 months compared to placebo in patients with advanced NSCLC. There are seven other Tyrosine kinase inhibitor entities in our investigational knowledgebase.

You can access up-to-date information on all drugs in the late stages of development with the Prescribe Right Pharmaceutical Pipeline Tracker.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.